Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06565195 · ClinicalTrials.gov registry record · Phase 1

A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease

A Phase 1 study of Parkinson's Disease, sponsored by Prevail Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
108
Enrollment target
4
Study locations

NCT06565195 is a Phase 1 study of Parkinson's Disease that is actively recruiting participants, run by Prevail Therapeutics. The registered enrollment target is 108 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (83% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06565195, a Phase 1 study of Parkinson's Disease, is actively recruiting participants, sponsored by Prevail Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
108 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, and PK/PD of LY3962681 in healthy volunteers and patients with Parkinson's disease. The study will be comprised of two parts, the Single Ascending Dose (SAD) study and the Multiple Ascending Doses (MAD) study. During the SAD portion of the study, healthy volunteers will receive a single dose of LY3962681 or placebo (artificial cerebrospinal fluid (aCSF), no active drug) given into the spinal fluid. During the MAD portion of the study, patients with Parkinson's disease will receive two doses of either LY3962681 or placebo (aCSF) administered into the spinal fluid. * The treatment period in the SAD study will be 1 day. The treatment period in the MAD study will be 2 days, 12 to 24 weeks apart. * The follow-up period in the SAD study will be up to 52 weeks. The follow-up period in the MAD study will be up to 52 weeks post Dose 2.

Conditions Studied

Parkinson's Disease

Interventions

  • DRUG LY3962681
  • OTHER Placebo (aCSF)

Study Locations (4)

Texas

  • Austin Clinic PPD - Austin

Ehime

  • Ehime University Hospital - Tōon

Oita Prefecture

  • Oita University Hospital - Yufu

Tokyo

  • P-One Clinic, Keikokai Medical Corporation - Hachiōji

Trial Details

FieldValue
Enrollment Target 108 participants
Start Date 2024-08-27
Est. Completion 2029-05-05
Phase Phase 1

Sponsor

Prevail Therapeutics

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06565195

The ClinicalTrials.gov registry entry for NCT06565195 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (83% lower). The listed sponsor is Prevail Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which LY3962681 is the first listed.

NCT06565195 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Texas, Ehime, Oita Prefecture.

Frequently Asked Questions

What is clinical trial NCT06565195 about?

NCT06565195 is a clinical study titled "A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease". The purpose of this study is to evaluate the safety, tolerability, and PK/PD of LY3962681 in healthy volunteers and patients with Parkinson's disease. The study will be comprised of two parts, the Single Ascending Dose (SAD) study and the Multiple Ascending Doses (MAD) study. During the SAD portion...

What is the current status of trial NCT06565195?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2024-08-27. Estimated completion is 2029-05-05.

What conditions does trial NCT06565195 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT06565195?

The interventions under investigation include: LY3962681 (DRUG), Placebo (aCSF) (OTHER).

Who is sponsoring clinical trial NCT06565195?

This trial is sponsored by Prevail Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06565195 being conducted?

This trial has 4 study locations across Texas, Ehime, Oita Prefecture, Tokyo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson's Disease

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.